PEOPLE - Kourion Therapeutics (Germany) makes appointment:
This article was originally published in Clinica
Kourion Therapeutics (Dusseldorf, Germany), a developer and manufacturer of cord blood-derrived stem cell products, has appointed Jurgen Peter as CFO and Christian van den Bos as vice-president of development and operations. Mr Peter, who has over 14 years of business management experience, most recently served as an equity investment manager at the Deutsche Beteiligungsgesellschaft and Dr van den Bos as director of biologics at Prospect Pharma.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.